Question · asked by 1 review
Deferasirox vs deferoxamine: End‐organ damage (incidence of diabetes)
- Population
- patients with managing transfusional iron overload in people with sickle cell disease
- Intervention
- Deferasirox
- Comparison
- deferoxamine
- Outcome
- End‐organ damage (incidence of diabetes)
It is very uncertain whether deferasirox changes end‐organ damage (incidence of diabetes) compared with deferoxamine (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Deferasirox vs deferoxamine End‐organ damage (incidence of diabetes) · patients with sickle cell disease and transfusional iron overload It is very uncertain whether deferasirox changes end‐organ damage (incidence of diabetes) compared with deferoxamine (very low certainty). Deferasirox for managing transfusional iron overload in people with sickle cell disease (2014) · Cochrane Headline outcomes only | RR 1.26 [0.05, 30.41] | 1 study · 191 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Deferasirox for managing transfusional iron overload in people with sickle cell disease 2014 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.